Frontlight ResearchEarly access
Ovarian cancer trials in China
185 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleRomiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
- Where
- Beijing
- Age
- 18 years and over
- People
- 220
- Run by
- Peking University People's Hospital
See details and how to joinNCT07586826 - Phase 3Taking peopleA Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer
- Where
- Changchun
- Age
- 18 years to 70 years
- People
- 60
- Run by
- tongweihua
See details and how to joinNCT07544030 - No phaseTaking peopleApplication of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
- Where
- Changchun
- Age
- 18 years to 70 years
- People
- 52
- Run by
- manxiaxia
See details and how to joinNCT07572409 - Phase 2Taking peopleA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
- Where
- Beijing, Bengbu, Changsha, Fuzhou, Guangzhou, Jinan, Kunming, Nanning, Shanghai, Shijiazhuang, Wuhan, Xiamen, Xi'an, Yibin, Zhengzhou
- Age
- 18 years to 75 years
- People
- 90
- Run by
- Shanghai Jiaolian Drug Research and Development Co., Ltd
See details and how to joinNCT06434610 - No phaseTaking peopleCtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 100
- Run by
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT05027828 - Phase 2/3Not yet taking people in ChinaTiaoshen Anti-cancer Protocol and CBT for Insomnia and Survival in Ovarian Cancer
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 360
- Run by
- Shanghai Municipal Hospital of Traditional Chinese Medicine
See details and how to joinNCT07550205 - Phase 2Taking peopleA Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
- Where
- Ji'nan
- Age
- 18 years to 75 years
- People
- 190
- Run by
- Shanghai Henlius Biotech
See details and how to joinNCT06769152 - Phase 3Taking peopleA Study of SHR-A1811 in Subjects With Ovarian Cancer
- Where
- Jinan, Wuhan
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT06828354 - Phase 1/2Taking peopleStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
- Where
- Baoding, Beijing, Binzhou, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Shanghai, Wuhan, Yunnan
- Age
- 18 years and over
- People
- 350
- Run by
- Evopoint Biosciences Inc.
See details and how to joinNCT06799637 - No phaseNot yet taking people in ChinaClinical Trial on Safety and Efficacy of Thoracoabdominal Endoscopic Surgical System for Pediatric Surgery
- Where
- Hangzhou, Wenzhou, Wuhan
- Age
- 0 years to 17 years
- People
- 64
- Run by
- Hangzhou Kangji Weijing Medical Robotics Co., Ltd.
See details and how to joinNCT07530133 - No phaseTaking peopleA Bidirectional Cohort Study on Prophylactic Resection Surgery in Populations at Moderate-to-High Risk for Hereditary Ovarian Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 480
- Run by
- Peking University Third Hospital
See details and how to joinNCT07532434 - Phase 1/2Taking peopleBiomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 72
- Run by
- Beijing Biotech
See details and how to joinNCT07523529 - No phaseTaking peopleEfficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study
- Where
- Changchun
- Age
- 18 years and over
- People
- 40
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07495384 - No phaseTaking peopleSingle-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)
- Where
- Changchun
- Age
- 18 years to 75 years
- People
- 98
- Run by
- The First Hospital of Jilin University
See details and how to joinNCT07495397 - No phaseTaking peopleTEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients
- Where
- Hangzhou
- Age
- 18 years to 65 years
- People
- 780
- Run by
- Zhejiang University
See details and how to joinNCT07480785 - Phase 1/2Taking peopleDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07480954 - Phase 1/2Taking peopleIntraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
- Where
- Beijing
- Age
- 18 years and over
- People
- 29
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07435701 - Phase 1Taking peopleA Study of PLB-002 in Advanced Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 100
- Run by
- Primelink BioTherapeitics(ShenZhen) Limited
See details and how to joinNCT07304128 - Phase 2Taking peopleNeoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 48
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07033819 - Phase 1/2Taking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Age
- 8 years to 85 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - Phase 1/2Taking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - No phaseTaking peopleSY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
- Where
- Hangzhou, Linyi
- Age
- 18 years to 75 years
- People
- 2
- Run by
- Cell Origin Biotech (Hangzhou) Co., Ltd.
See details and how to joinNCT06562647 - Phase 2Not yet taking people in ChinaIparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07407452 - Phase 1Taking peopleA Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
- Where
- Changchun, Jinan
- Age
- 18 years and over
- People
- 9
- Run by
- Shanghai Best-Link Bioscience, LLC
See details and how to joinNCT06738966 - Phase 1/2Taking peopleA First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
- Where
- Tianjin
- Age
- 18 years and over
- People
- 152
- Run by
- Jacobio Pharmaceuticals Co., Ltd.
See details and how to joinNCT04686682